ANTHRASIL Drug Profile

Summary for Tradename: ANTHRASIL

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ANTHRASIL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ANTHRASIL Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ANTHRASIL Derived from Patent Text Search

No patents found based on company disclosures

Anthrax Treatment Market Dynamics and Financial Trajectory: Focus on Anthrasil

Introduction to Anthrasil

Anthrax, caused by the bacterium Bacillus anthracis, is a serious and sometimes fatal illness. Anthrasil, a key component in the treatment of anthrax, is an anthrax immune globulin intravenous (AIGIV) used for the treatment of inhalation anthrax.

Market Overview of Anthrax Treatment

The global anthrax treatment market is experiencing significant growth, driven by advancements in biotechnology, increased government funding, and the need for effective countermeasures against bioterrorism.

• Market Size and Growth: The global anthrax treatment market was valued at approximately USD 332.06 million in 2022 and is projected to reach USD 636.65 million by 2031, growing at a CAGR of 7.5% during the forecast period[1][4].

Segmentation of the Anthrax Treatment Market

By Treatment Type

• The market is segmented into antibiotics, monoclonal antibodies, and others. Antibiotics, such as Ciprofloxacin and Doxycycline, dominate the market, but monoclonal antibodies like obiltoxaximab (Anthim) and raxibacumab are gaining traction due to their targeted efficacy against anthrax toxins[1][4].

By End Use

• The market is segmented into hospitals and clinics, ambulatory surgery centers, government agencies, and others. Government agencies account for a significant portion of the revenue, with nearly 86.7% of Emergent Biosolutions' product sales going to government agencies[1].

Role of Anthrasil in the Market

Mechanism and Approval

• Anthrasil is an anthrax immune globulin intravenous (AIGIV) derived from the plasma of donors who have been vaccinated against anthrax. It is used as an adjunct to antibiotic treatment for inhalation anthrax. The U.S. FDA approved Anthrasil in 2015 for this indication[1].

Market Impact

• Anthrasil is part of the broader category of immunoglobulins, which are gaining importance due to their ability to provide immediate immunity against anthrax. This segment, although smaller compared to antibiotics, is crucial for post-exposure prophylaxis and treatment[4].

Financial Performance of Key Players

Emergent BioSolutions

• Emergent BioSolutions is a leading player in the anthrax treatment market, with products like BioThrax (Anthrax Vaccine Adsorbed) and Anthrasil.
  • Revenue Trends: In Q1 2023, Emergent BioSolutions reported total revenues of $165.1 million, with a significant portion coming from product sales, including anthrax-related medical countermeasures (MCMs)[2].
  • Government Contracts: The company derives a substantial portion of its revenue from government contracts. For instance, the contract with BARDA (Biomedical Advanced Research and Development Authority) for the procurement of AV7909 and BioThrax is a key contributor to their financial performance[3].

Financial Metrics

• Product Sales: The sales of anthrax MCMs, including Anthrasil, have seen fluctuations. In Q4 2023, the anthrax MCM segment saw a significant increase of 98% compared to Q4 2022, highlighting the ongoing demand for these products[5].

Government Funding and Stockpiling Strategies

Impact on Market Growth

• Government funding and stockpiling strategies are critical drivers of the anthrax treatment market. Programs like the National Stockpile Strategy and the Anthrax Vaccine Immunization Program conducted by the U.S. Department of Defense have significantly boosted the market[1].

BARDA Contracts

• Contracts with BARDA, such as the one for AV7909, which includes procurement options for up to 50 million doses, demonstrate the government's commitment to stockpiling anthrax treatments. These contracts not only ensure a steady revenue stream for companies like Emergent BioSolutions but also drive innovation and research in anthrax therapeutics[3].

Regional Market Dynamics

North America

• North America, particularly the U.S., dominates the global anthrax treatment market due to high government funding and the presence of key players. The region's market size was valued at USD 141.7 million in 2023 and is expected to grow at a CAGR of 7.8% over the forecast period[1][4].

Asia Pacific and Other Regions

• The Asia Pacific region is expected to be the fastest-growing market, driven by increasing awareness and government initiatives. India, in particular, is predicted to show lucrative growth during the forecast period[1][4].

Challenges and Opportunities

Regulatory Approvals

• New drug approvals, such as the FDA approval of obiltoxaximab (Anthim) in 2016, are key factors driving market growth. However, the regulatory approval process can be lengthy and challenging, posing a risk to market dynamics[1].

Research and Development

• Ongoing research and development in anthrax therapeutics, including the discovery of new monoclonal antibodies, present significant opportunities for market expansion. Innovations in biotechnology are enhancing treatment efficacy and contributing to market growth[4].

Key Takeaways

• The global anthrax treatment market is growing steadily, driven by government funding, advancements in biotechnology, and the need for effective countermeasures against bioterrorism.
• Anthrasil, as an adjunct to antibiotic treatment for inhalation anthrax, plays a crucial role in the market.
• Key players like Emergent BioSolutions are benefiting from government contracts and stockpiling strategies.
• Regional dynamics, particularly in North America and the Asia Pacific, are shaping the market's growth trajectory.

FAQs

What is Anthrasil used for?

Anthrax immune globulin intravenous (AIGIV), or Anthrasil, is used as an adjunct to antibiotic treatment for inhalation anthrax.

Which company produces Anthrasil?

Anthraxil is produced by Emergent BioSolutions.

What is the projected growth rate of the global anthrax treatment market?

The global anthrax treatment market is projected to grow at a CAGR of 7.5% from 2023 to 2031[1].

Which region dominates the global anthrax treatment market?

North America, particularly the U.S., dominates the global anthrax treatment market due to high government funding and the presence of key players[1].

What are the main drivers of the anthrax treatment market?

The main drivers include government funding, advancements in biotechnology, and the need for effective countermeasures against bioterrorism[1][4].

Sources

1. Straits Research: Global Anthrax Treatment Market Size, Share and Forecast to 2031.
2. GlobeNewswire: Emergent BioSolutions Reports Financial Results For First Quarter 2023.
3. Annual Reports: Emergent BioSolutions Annual Report 2020.
4. Global Market Insights: Anthrax Treatment Market Size, Share & Trend Analysis - 2032.
5. Stock Titan: Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results.

Last updated: 2024-12-18